0HTC Stock Overview
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Cara Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.69 |
| 52 Week High | US$4.67 |
| 52 Week Low | US$0.50 |
| Beta | 0.70 |
| 1 Month Change | -25.67% |
| 3 Month Change | 26.94% |
| 1 Year Change | -83.03% |
| 3 Year Change | -97.40% |
| 5 Year Change | -96.36% |
| Change since IPO | -95.44% |
Recent News & Updates
Recent updates
Shareholder Returns
| 0HTC | GB Pharmaceuticals | GB Market | |
|---|---|---|---|
| 7D | -12.9% | -1.2% | -0.7% |
| 1Y | -83.0% | -5.0% | -1.8% |
Return vs Industry: 0HTC underperformed the UK Pharmaceuticals industry which returned -5% over the past year.
Return vs Market: 0HTC underperformed the UK Market which returned -1.8% over the past year.
Price Volatility
| 0HTC volatility | |
|---|---|
| 0HTC Average Weekly Movement | 15.6% |
| Pharmaceuticals Industry Average Movement | 8.7% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in GB Market | 11.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: 0HTC's share price has been volatile over the past 3 months.
Volatility Over Time: 0HTC's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 55 | Chris Posner | www.caratherapeutics.com |
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.
Cara Therapeutics, Inc. Fundamentals Summary
| 0HTC fundamental statistics | |
|---|---|
| Market cap | US$37.72m |
| Earnings (TTM) | -US$118.51m |
| Revenue (TTM) | US$20.97m |
1.8x
P/S Ratio-0.3x
P/E RatioIs 0HTC overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 0HTC income statement (TTM) | |
|---|---|
| Revenue | US$20.97m |
| Cost of Revenue | US$113.55m |
| Gross Profit | -US$92.58m |
| Other Expenses | US$25.93m |
| Earnings | -US$118.51m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.17 |
| Gross Margin | -441.53% |
| Net Profit Margin | -565.21% |
| Debt/Equity Ratio | 65.0% |
How did 0HTC perform over the long term?
See historical performance and comparison